Shares of Nektar Therapeutics (NKTR) have been struggling lately and have lost 11.5% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could ...

Nektar Therapeutics Stock Performance NASDAQ:NKTR opened at $0.89 on Friday. Nektar Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.93. The stock has a fifty day moving average of ...

Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.